Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that ...

This study elucidated the mechanism underlying drug resistance induced by CDK4/6i as a single agent ... In their manuscript, Armand and colleagues investigate the potential of continuing CDK4/6 ...

Insilico Medicine Inc. has disclosed substituted thiazole compounds acting as cyclin-dependent kinase (CDK) inhibitors potentially useful for the treatment of cancer. Insilico Medicine identifies CDK2 ...

A team led by UT Southwestern scientists has discovered a mechanism that promotes metastasis ... developed the first AKT3-specific molecule inhibitor, allowing the investigators to shut down ...

The solid tumor oncology segment is developing promising candidates, including a CDK2 inhibitor that has shown early efficacy in platinum-resistant ovarian cancer. The company is making a ...

The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an app Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1 ...

The solid tumor oncology segment is developing promising candidates, including a CDK2 inhibitor that has shown early efficacy in platinum-resistant ovarian cancer. The company is making a significant ...